Medovex Corporation Announces Columbia Regulatory Approval and Issuance of Two New US Patent Approvals

ATLANTA, April 05, 2018 -- Medovex Corp. (OTCQB:MDVX) ("Medovex" or the "Company"), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to chronic back pain, a non-addictive, non-opioid drug alternative capable of restoring a patient to a more normal and active lifestyle, today announced that the Company has received Columbia regulatory approval for its DenerveX System as well as being issued two US patents and a trademark.

The Company’s INVIMA product approval for Colombia was granted for a period of 10 years, allowing the Company immediate product release to its first two signed distributors, located in Medellin and in Bogota.

Additionally, the Company has been issued two US patents and a trademark covering the EU for “Rotacapsulation”.

• Patent No: US D810,290S Surgical Portal Driver
• Patent No: US 9,883,882 Minimally Invasive Methods for Spinal Facet Therapy to alleviate pain and associated surgical tools, kits and instructional media

Manfred Sablowski, Medovex Senior Vice President of Global Sales & Marketing stated, “We are pleased that our DenerveX System has received INVIMA regulatory product approval for Columbia, one of the biggest economies in Latin America. We anticipate this will help us to increase our sales & marketing footprint throughout the Americas.”

Sablowski continued, “We at Medovex are confident that doctors will appreciate the unique features and the reliable 'Rotacapsulation' treatment modality offered by our DenerveX System as they treat patients suffering from often debilitating pain associated with the Facet Joints.”

Please also follow us on Facebook at https://www.facebook.com/medovex/.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX System, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com.

Safe Harbor Statement                                                     

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information

• Medovex Corp.
  Jason Assad
  470-505-9905
  [email protected]